ArticleHealth science reports2025
The Safety and Efficacy of Intravascular Lithotripsy in the Treatment of Severe Coronary Artery Calcification in 261 Cases: A Retrospective Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Calcified Coronary Lesions-A Review of Plaque Modification Methods.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery calcification is strongly linked to factors such as advanced age, dyslipidemia, and chronic kidney disease. Severe coronary artery calcification significantly elevates the complexity and risk of percutaneous coronary intervention (PCI), potentially giving rise to complications such as incomplete stent expansion, restenosis, and thrombosis. Intravascular lithotripsy (IVL), a novel approach, can break up calcified plaques and facilitate stent delivery and expansion. Nevertheless, its comprehensive safety and efficacy in pretreating severe coronary artery calcification lesions remain uncertain, and research data is relatively scarce compared to traditional techniques, especially in the large hospital setting of Henan with a considerable population base. Aims: To retrospectively analyze the safety and efficacy of IVL in the treatment of severe coronary artery calcification in 261 cases. Methods: From January 2022 to March 2024, 261 patients with at least one coronary artery lesion diagnosed as severe calcification and undergoing PCI based on IVL in Fuwai Central China Cardiovascular Hospital and Henan Provincial People's Hospital were selected for the study. A retrospective analysis was conducted on 272 diseased vessels treated with IVL for PCI. The primary endpoint was procedural success, while the main safety endpoints were no cardiac death, myocardial infarction, and target vessel revascularization within 30 days. Results: Among the 261 patients, 234 (89.7%) had acute coronary syndrome (ACS), including 195 (74.7%) with non-ST-segment elevation myocardial infarction (NSTEMI). Various techniques like noncompliant balloon, cutting balloon, and orbital grinding were employed for IVL preparation, and the proportion of direct IVL treatment was 8.8% (24 cases). The minimum lumen area significantly increased from (1.5 ± 0.6) mm² before treatment to (7.2 ± 1.8) mm² after treatment, with an acute gain rate of (243 ± 105)%, ( Conclusions: As a new technology for modifying calcified plaques, the IVL system proves to be safe, effective, and straightforward to operate, offering a new and preferred option for patients with severe coronary calcified lesions, particularly those with ACS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.